Your browser doesn't support javascript.
loading
Follow-up of cystic pineal glands in retinoblastoma patients does not increase detection of pineal trilateral retinoblastoma.
de Bloeme, Christiaan M; Jansen, Robin W; de Haan, Joeka; Pieperjohanns, Debbie; Casseri, Tommaso; Gironi, Federica; Pasca, Alessandra; Ketteler, Petra; Moll, Annette C; Koob, Meriam; Sirin, Selma; Maeder, Philippe; Galluzzi, Paolo; Göricke, Sophia; de Graaf, Pim; de Jong, Marcus C.
Affiliation
  • de Bloeme CM; European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. Electronic address: c.debloeme@amsterdamum
  • Jansen RW; European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • de Haan J; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Pieperjohanns D; Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
  • Casseri T; Department of Neuroimaging and Neurointervention, Siena University Hospital, Siena, Italy.
  • Gironi F; Department of Pediatrics and Neonatology, Siena University Hospital, Siena, Italy.
  • Pasca A; Department of Pediatrics and Neonatology, Siena University Hospital, Siena, Italy.
  • Ketteler P; Department of Pediatric Oncology, University Hospital Essen, Essen, Germany.
  • Moll AC; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Koob M; European Retinoblastoma Imaging Collaboration (ERIC); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
  • Sirin S; European Retinoblastoma Imaging Collaboration (ERIC); Department of Diagnostic Imaging, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Maeder P; European Retinoblastoma Imaging Collaboration (ERIC); Department of Radiology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
  • Galluzzi P; European Retinoblastoma Imaging Collaboration (ERIC); Department of Neuroimaging and Neurointervention, Siena University Hospital, Siena, Italy.
  • Göricke S; European Retinoblastoma Imaging Collaboration (ERIC); Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
  • de Graaf P; European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • de Jong MC; European Retinoblastoma Imaging Collaboration (ERIC); Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Am J Ophthalmol ; 2024 Jul 09.
Article in En | MEDLINE | ID: mdl-38992673
ABSTRACT

PURPOSE:

To evaluate the effectiveness of baseline screening and follow-up with MRI to detecting trilateral retinoblastoma (TRb) and assessing the risk of TRb development.

DESIGN:

Prospective multicenter cohort study

METHODS:

A total of 607 retinoblastoma patients from 2012 through 2022 were included and followed up until 1-9-2023. At each center a neuroradiologist categorized pineal glands on baseline and follow-up scans into four groups (A) normal, (B) cystic gland, (C) suspicious gland, or (D) TRb. Different follow-up schedules were assigned to each category. Categories (B) and (C) were followed-up with MRI after approximately 3-months and after another 3 months if suspicion remained. On each MRI, they measured the height and width, evaluated the aspect (solid, partly cystic and completely cystic) of the pineal gland and evaluated radiological features suspicious of pineal TRb. The effectiveness of the current TRb screening method was assessed by evaluating its sensitivity and specificity to detect TRb. Determining the TRb incidence was a secondary outcome measure.

RESULTS:

Heritable retinoblastoma patients had a risk of 3.78% to develop TRb. One out of four pineal TRbs was detected during a follow-up scan and four out of five non-pineal TRbs were detected on the baseline MRI. Screening for pineal TRb had a sensitivity of 25% and specificity of 100%, for non-pineal TRb the sensitivity was 80%. It required 494 follow-up scans to detect one pineal TRb. However, when restricting the follow-up to solely suspicious glands, only 22 scans were required to detect one pineal TRb.

CONCLUSION:

During extended follow-up after baseline MRI, only one pineal trilateral retinoblastoma was detected in our study. Follow-up after three months should be restricted to patients with a suspicious pineal gland defined as irregularly thickening of the cyst wall (>2mm), fine nodular aspect of the cyst wall or when a solid or cystic gland exceeds the upper 99% prediction interval for size; patients with an unsuspicious cystic gland should not be followed up. Baseline MRI screening was able to detect most non-pineal trilateral retinoblastomas.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Ophthalmol Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Am J Ophthalmol Year: 2024 Document type: Article